ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Valve Disease

May 23, 2016
This video demonstrates a valve-sparing aortic root replacement with an expansible ring.
May 10, 2016
This prospective study showed that surgical aortic valve replacement and TAVI can be performed in patients with EuroSCORE <4% with similar 30-day mortality rates. Surgical aortic valve replacement had significantly better 3-year outcome than TAVI. These data suggest that expanding the use of TAVI in low-risk patients may not be justified.
May 9, 2016
This presentation describes the basic surgical techniques and steps required for successfully performing a valve-sparing root replacement.
May 5, 2016
This article summarizes the current status of robotic approaches to mitral valve repair.  The technique is suitable to all types of degenerative mitral valve disease, and the outcomes are similar to those for open repair. 
April 25, 2016
This video shows an aortic annulus enlargement using a modified Manouguian technique without opening the left atrium roof.
April 18, 2016
The authors present the minimally invasive repair of a stenotic bicuspid aortic valve and ascending aorta aneurysm through a J-shaped ministernotomy approach.
April 12, 2016
The authors used a single institution data base to assess very long-term outcomes after AVR to determine the effects of prosthesis-patient mismatch.  Among 673 pts, 24% had mismatch.  Mean follow-up was nearly 18 years.  On multivariable analysis, mismatch was not a significant determinant of long-term survival.
April 5, 2016
In this manuscript the authors report on their findings in a systematic review and meta-analysis of 18 studies looking into the effect on outcomes of balloon predilatation in patients undergoing transcatheter aortic valve implantation (TAVI).
April 3, 2016
Neil Moat, one of the busiest British surgeons involved directly and consistently in TAVR, discusses PARTNER 2 and SURTAVI, paying particular attention to the health economics of low-risk TAVR and the implication of reduced profile devices.
April 3, 2016
The PARTNER 2A trial randomized 2032 patients at intermediate operative risk (mean STS score of 6) to undergo either transcatheter or surgical aortic valve replacement. The primary endpoint of all-cause death or disabling stroke at 2 years was comparable for the two treatments: TAVR 19.3% versus SAVR 21.1%.

Pages